IGMS News and Press, IGM Biosciences Inc. From 06/21/23

MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, i...

MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at ...

MOUNTAIN VIEW, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) a...

– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that i...

2023-05-12 09:50:31 ET IGM Biosciences press release ( NASDAQ: IGMS ): Q1 GAAP EPS of -$1.33 beats by $0.01 . Revenue of $0.52M misses by $0.79M . For further details see: IGM Biosciences GAAP EPS of -$1.33 beats by $0.01, revenue of $0.52M misses by $0.79M

– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle o...

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside...

MOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of six posters at the upcoming American Association for Cancer Rese...

2023-03-31 23:06:06 ET IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Fred Schwarzer – Chief Executive Officer Misbah Tahir – Chief Financial Officer Chris Takimoto – Chief Medical...